Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

Am J Cardiovasc Drugs. 2020 Jun;20(3):217-221. doi: 10.1007/s40256-020-00406-0.

Abstract

There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Antihypertensive Agents / pharmacology
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / physiology
  • COVID-19
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / metabolism
  • Comorbidity
  • Confounding Factors, Epidemiologic
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / metabolism
  • Global Health
  • Humans
  • Pandemics*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / metabolism
  • Renin-Angiotensin System / drug effects*
  • Risk Assessment
  • SARS-CoV-2
  • Severity of Illness Index

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents